NasdaqGM - Nasdaq Real Time Price USD

CERo Therapeutics Holdings, Inc. (CERO)

1.1450 -0.0150 (-1.29%)
As of 3:27 PM EDT. Market Open.
Loading Chart for CERO
DELL
  • Previous Close 1.1600
  • Open 1.1100
  • Bid 1.1400 x 100
  • Ask 1.1800 x 100
  • Day's Range 1.1100 - 1.1999
  • 52 Week Range 1.1100 - 12.8000
  • Volume 103,158
  • Avg. Volume 1,133,396
  • Market Cap (intraday) 16.859M
  • Beta (5Y Monthly) -0.06
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies. The company was incorporated in 2021 and is based in South San Francisco, California.

www.cero.bio

8

Full Time Employees

December 31

Fiscal Year Ends

Recent News: CERO

Performance Overview: CERO

Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

CERO
89.59%
S&P 500
9.97%

1-Year Return

CERO
89.46%
S&P 500
27.19%

3-Year Return

CERO
--
S&P 500
14.86%

5-Year Return

CERO
--
S&P 500
14.86%

Compare To: CERO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: CERO

Valuation Measures

Annual
As of 5/13/2024
  • Market Cap

    17.08M

  • Enterprise Value

    14.55M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -7.20%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -2.54M

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    96.87k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    5.11M

Research Analysis: CERO

Company Insights: CERO

Research Reports: CERO

People Also Watch